{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:50:05Z","timestamp":1787759405402,"version":"build-2784847793"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,5]]},"abstract":"ABSTRACT<\/jats:title>\n \n The\n in vitro<\/jats:italic>\n activity of ceftazidime-avibactam was evaluated against 34,062 isolates of\n Enterobacteriaceae<\/jats:named-content>\n from patients with intra-abdominal, urinary tract, skin and soft-tissue, lower respiratory tract, and blood infections collected in the INFORM (International Network For Optimal Resistance Monitoring) global surveillance study (176 medical center laboratories in 39 countries) in 2012 to 2014. Overall, 99.5% of\n Enterobacteriaceae<\/jats:named-content>\n isolates were susceptible to ceftazidime-avibactam using FDA approved breakpoints (susceptible MIC of \u22648 \u03bcg\/ml; resistant MIC of \u226516 \u03bcg\/ml). For individual species of the\n Enterobacteriaceae<\/jats:named-content>\n , the ceftazidime-avibactam MIC inhibiting \u226590% of isolates (MIC\n 90<\/jats:sub>\n ) ranged from 0.06 \u03bcg\/ml for\n Proteus<\/jats:named-content>\n species to 1 \u03bcg\/ml for\n Enterobacter<\/jats:named-content>\n spp. and\n Klebsiella pneumoniae<\/jats:named-content>\n . Carbapenem-susceptible isolates of\n Escherichia coli<\/jats:named-content>\n ,\n K. pneumoniae<\/jats:named-content>\n ,\n Klebsiella oxytoca<\/jats:named-content>\n , and\n Proteus mirabilis<\/jats:named-content>\n with a confirmed extended-spectrum \u03b2-lactamase (ESBL) phenotype, or a ceftazidime MIC of \u226516 \u03bcg\/ml if the ESBL phenotype was not confirmed by clavulanic acid inhibition, were characterized further to identify the presence of specific ESBL- and plasmid-mediated AmpC \u03b2-lactamase genes using a microarray-based assay and additional PCR assays. Ceftazidime-avibactam demonstrated potent activity against molecularly confirmed ESBL-producing (\n n<\/jats:italic>\n = 5,354; MIC\n 90<\/jats:sub>\n , 0.5 \u03bcg\/ml; 99.9% susceptible), plasmid-mediated AmpC-producing (\n n<\/jats:italic>\n = 246; MIC\n 90<\/jats:sub>\n , 0.5 \u03bcg\/ml; 100% susceptible), and ESBL- and AmpC-producing (\n n<\/jats:italic>\n = 152; MIC\n 90<\/jats:sub>\n , 1 \u03bcg\/ml; 100% susceptible) isolates of\n E. coli<\/jats:named-content>\n ,\n K. pneumoniae<\/jats:named-content>\n ,\n K. oxytoca<\/jats:named-content>\n , and\n P. mirabilis<\/jats:named-content>\n . We conclude that ceftazidime-avibactam demonstrates potent\n in vitro<\/jats:italic>\n activity against globally collected clinical isolates of\n Enterobacteriaceae<\/jats:named-content>\n , including isolates producing ESBLs and AmpC \u03b2-lactamases.\n <\/jats:p>","DOI":"10.1128\/aac.02286-15","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T04:04:31Z","timestamp":1456805071000},"page":"2849-2857","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":117,"title":["Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC \u03b2-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014"],"prefix":"10.1128","volume":"60","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Biedenbach","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna M.","family":"Kazmierczak","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12023"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-090110-102911"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02625-14"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03057-14"},{"key":"e_1_3_2_9_2","volume-title":"Avycaz prescribing information","author":"Forest Pharmaceuticals, Inc","year":"2014","unstructured":"Forest Pharmaceuticals, Inc. 2014. Avycaz prescribing information. Forest Pharmaceuticals, Inc., Cincinnati, OH."},{"key":"e_1_3_2_10_2","volume-title":"Performance standards for antimicrobial susceptibility testing, 25th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing, 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_11_2","volume-title":"Approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_12_2","volume-title":"Tygacil FDA prescribing information","author":"Pfizer, Inc","year":"2010","unstructured":"Pfizer, Inc. 2010. Tygacil FDA prescribing information. Pfizer, Inc., Collegeville, PA."},{"key":"e_1_3_2_13_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, valid from 2015-01-01","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2015","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, valid from 2015-01-01. European Committee on Antimicrobial Susceptibility Testing, Vaxjo, Sweden. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05186-14"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.05.024"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06115-11"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2012.034"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182886377"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02123-13"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01896-13"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku025"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.07.005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr240"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-14"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02894-14"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03579-14"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku237"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02286-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02286-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:46:14Z","timestamp":1645476374000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02286-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1128\/AAC.02286-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02286-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"2015-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}